Agendia B.V.

Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting

    Huntington Beach, California and Amsterdam (ots/PRNewswire) - Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia, the University of California San Francisco and the Netherlands Cancer Institute will present data from multiple studies at the American Society of Clinical Oncology Annual Meeting, May 29 - June 2, 2009, in Orlando, Florida.

    The study results further underpin the broad predictive and prognostic power of Agendia's breast cancer recurrence test MammaPrint(R) and highlight promising data on Agendia's new colon cancer recurrence test, ColoPrint(TM). Visitors can meet the Agendia team in booth #2014 and study results will be discussed at the following sessions:

@@start.t1@@      Date: Saturday, May 30, 2009
      Abstract #512
      Time: 5:00PM - 5:15PM
      Location: Level 2, West Hall D1
      The 70-gene profile and chemotherapy benefit in 1,600 breast cancer
      R. A. Bender, M. Knauer, E. J. Rutgers, A. M. Glas, F. A. de Snoo, S. C.
      Linn, L. J. Van 't Veer
      Date: Saturday, May 30, 2009
      Abstract # LBA515
      Time: 3:00PM - 6:00PM
      Location: Level 2, West Hall D1
      Breast cancer molecular profiles predict tumor response of neoadjuvant
      Doxorubicin and Taxol, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)
      L. J. Esserman, C. Perou, M. Cheang, A. DeMichele, L. Carey, L. J. van 't
      Veer, J. Gray, E. Petricoin, K. Conway, D. Berry, I-Spy Investigators
      Date: Saturday, May 30, 2009
      Abstract #6570
      Time: 2:00PM - 6:00PM
      Location: Level 2, West Hall C
      Cost effectiveness of targeting chemotherapy with the 70-gene
      prognostic signature in early stage breast cancer (ESBC) patients
      K. B. Tong, E. Chen, G. Brink, R. Bender, F. de Snoo, J. Malin
      Date: Sunday, May 31, 2009
      Abstract #535
      Time: 8:00AM - 12:00PM
      Location: Level 2, West Hall D1, W240A
      Outcome prediction by the 70-gene profile in the context of the National
      Comprehensive Cancer Network (NCCN) guideline
      F. A. de Snoo, M. Knauer, R. A. Bender, L. Stork-Sloots, E. J. Rutgers,
      A. M. Glas, S. C. Linn, L. J. Van 't Veer
      Date: Sunday, May 31, 2009
      Abstract #4036
      Time: 8:00 AM - 12:00 PM
      Location: Level 2, West Hall C
      Development and validation of a robust prognostic and predictive
      signature for colorectal cancer (CRC) patients
      A. M. Glas, P. Roepman, R. Salazar, G. Capella, V. Moreno, J. Westerga,
      P. J. Kuppen, I. Simon, L. J. Van 't Veer, R. Tollenaar
      Date: Sunday, May 31, 2009
      Abstract #518
      Time: 8:00AM - 12:00PM
      Location: Level 2, West Hall D1, W240A
      Early determination of metastatic potential in breast cancer: the 70-gene
      signature in small tumors
      M. Knauer, S. Mook, V. Retèl, M. Kok, J. Wesseling, A. M. Glas, E. J.
      Rutgers, L. J. van 't Veer, S. C. Linn
      Date: Monday, June 01, 2009
      Abstract #11083
      Time: 1:00PM - 5:00PM
      Location: Level 2, West Hall C
      Combining multi-gene profiling of molecular subtypes with the 70-gene
      profile for classification of breast cancer
      L. Stork-Sloots, O. Krijgsman, P. Roepman, F. A. de Snoo, R. A. Bender,
      A. M. Glas@@end@@

    About MammaPrint(R)

    MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

    All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

    About Agendia

    Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. The Company was awarded the 2008 North American Oncology Clinical Diagnostics Healthcare Innovation Award by Frost & Sullivan. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar:

Media contacts: Hans Herklots, Agendia, +31-20-462-1557 Office,
+31-620-083-509 Mobile, Valerie Delva,
Ricochet Public Relations, +1-212-679-3300 x131 Office,
+1-917-975-3191 Mobile,

Weitere Meldungen: Agendia B.V.

Das könnte Sie auch interessieren: